Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching. [PDF]
PLoS ONE, 2018 Current treatment with vasodilators for pulmonary hypertension associated with respiratory diseases is limited by their inhibitory effect on hypoxic pulmonary vasoconstriction (HPV) and uncoupling effects on ventilation-perfusion (V'/Q'). Hypoxia is also
Virginia Chamorro +11 more
doaj +3 more sources
Respiratory Medicine Case Reports, 2017 Riociguat is a novel soluble guanylate cyclase stimulator that is approved for the treatment of patients with pulmonary arterial hypertension (PAH) and patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent/recurrent
Asger Andersen +3 more
doaj +2 more sources
Analysis of riociguat and desmethyl riociguat by UPLC-MS/MS and its interaction with quercetin [PDF]
Frontiers in PharmacologyRiociguat, an orally soluble guanylate cyclase (sGC)-promoting drug, is mainly used in the clinical treatment of pulmonary hypertension (PH). In this study, a novel ultra-performance liquid chromatography-tandem mass spectrometry method was developed to ...
Qingqing Li +4 more
doaj +2 more sources
Population pharmacokinetics of riociguat and its metabolite in patients with chronic thromboembolic pulmonary hypertension from routine clinical practice [PDF]
Pulmonary Circulation, 2020 Pharmacokinetic data for riociguat in patients with chronic thromboembolic pulmonary hypertension (CTEPH) have previously been reported from randomized clinical trials, which may not fully reflect the population encountered in routine practice.
Danica Michaličková +11 more
doaj +2 more sources
The effect of Riociguat on cardiovascular function and efficiency in healthy, juvenile pigs [PDF]
Physiological Reports, 2020 Introduction Riociguat is a soluble guanylate cyclase stimulator approved for the treatment of pulmonary hypertension. Its effect on cardiometabolic efficiency is unknown.
Torvind Næsheim +2 more
doaj +2 more sources
Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study [PDF]
BMC Pulmonary Medicine, 2017 Background Following positive results from the Phase III CHEST-1 study in patients with inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), the Phase IIIb CTEPH early access study (EAS) was designed to assess the ...
Vallerie V. McLaughlin +19 more
doaj +2 more sources
Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension
Drug Design, Development and Therapy, 2017 Tian-Yu Lian, Xin Jiang, Zhi-Cheng Jing State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic ...
Lian TY, Jiang X, Jing ZC
doaj +1 more source
Effect of Riociguat on Adenine-Induced Chronic Kidney Disease in Rats
BiologyRiociguat is a soluble guanylate cyclase (sGC) activator that increases the levels of cyclic guanosine monophosphate (cGMP). cGMP is known to play a key role in regulating kidney function.
Aly M. Abdelrahman +4 more
doaj +2 more sources
Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies) [PDF]
Pulmonary Circulation, 2020 Many patients with pulmonary arterial hypertension do not achieve treatment goals with monotherapy, and therefore combination therapy is becoming the standard of care.
Hossein-Ardeschir Ghofrani +10 more
doaj +2 more sources
The Therapeutic Efficacy of Drugs Targeting the NO-sGC-cGMP Pathway in Treatment of Patients With Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review. [PDF]
Pulm CircABSTRACT Chronic thromboembolic pulmonary hypertension (CTEPH) is a distinct and potentially curable form of pulmonary hypertension; however, a substantial proportion of patients remain inoperable or experience persistent or recurrent disease. Pharmacological therapies targeting the nitric oxide–soluble guanylate cyclase–cyclic guanosine monophosphate (
Alqarni AA +9 more
europepmc +2 more sources